<p>Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025.</p>

Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025.

In conversation with... Neal Shore

The Lancet (www.thelancet.com) is a weekly medical journal, renowned for the publication of high-quality peer-reviewed research and reviews from around the world. In the Podcasts our editors discuss journal highlights, including interviews with authors of key articles to provide context and insight to advancements in medicine and health worldwide.

Share In conversation with... Neal Shore

Sign up to save your podcasts

In conversation with... Neal Shore

In conversation with... Neal Shore